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Background: Nebivolol is a highly β1-selective blocker with direct vasodilating properties mediated by endothelial cell (EC)-dependent nitric oxide 
(NO) release. The pharmacologic basis for enhanced NO bioavailability in human ECs with nebivolol is not fully understood but may involve multiple 
receptor-dependent pathways. In this study, we tested the effects of nebivolol on ATP- and β2/β3 receptor-dependent NO release.
Methods: The effects of nebivolol in EC-dependent NO release were evaluated with amperometric approaches in human umbilical vein endothelial 
cells (HUVECs) isolated from white and black American donors. The ability of nebivolol to produce ATP-dependent NO release was tested with 
inhibitors of this autocrine pathway, including purinergic P2Y receptor blockers (suramin, reactive blue 2) and Gd3+, an inhibitor of ATP-release 
channels. The role of β2 and β3 -receptors in NO release was evaluated with specific agonists (procaterol, L-755,507) and antagonists (ICI-118551, 
SR59230A) of these receptors (respectively). The effects of nebivolol on NO release were compared to atenolol.
Results: Nebivolol stimulated NO release from ECs from white and black American donors in a dose-dependent fashion starting at nanomolar 
concentrations. This increase in NO bioavailability correlated with ATP release and could be blocked reversibly with inhibitors of the ATP autocrine 
pathway. At equimolar concentrations, nebivolol-induced NO release was blocked with a β3-receptor antagonist while a β3-receptor agonist 
enhanced NO release. Modulators of β2-receptors had no significant effect on nebivolol activity. Atenolol failed to stimulate either NO or ATP release 
under identical conditions.
Conclusion: Nebivolol stimulated NO release in human endothelial cells through ATP-dependent autocrine pathway and β3-receptor interactions. 
These findings provide further insights into the pharmacologic basis for the direct vasodilatory properties of nebivolol.
